AI assistant
Sending…
ARS Pharmaceuticals, Inc. — Director's Dealing 2022
Dec 9, 2022
32159_dirs_2022-12-09_c254b383-eade-49f1-9357-e75633632445.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2022-12-06
Reporting Person: Dorsey Brian (Chief Operating Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $0.63 | 2028-11-28 | Common Stock (141828) | Direct | |
| Stock option (right to buy) | $0.79 | 2029-03-06 | Common Stock (85687) | Direct | |
| Stock option (right to buy) | $0.84 | 2029-07-04 | Common Stock (127645) | Direct | |
| Stock option (right to buy) | $0.84 | 2029-12-16 | Common Stock (82733) | Direct | |
| Stock option (right to buy) | $1.44 | 2031-10-05 | Common Stock (82733) | Direct | |
| Stock option (right to buy) | $1.44 | 2031-12-13 | Common Stock (82733) | Direct |
More from ARS Pharmaceuticals, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 13
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5